Phathom Pharmaceuticals Inc. (PHAT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Phathom Pharmaceuticals I... (PHAT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.78

0.16 (2.42%)

At close: Jan 14, 2025, 3:59 PM

6.79

0.22%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	2.72
Market Cap	463.26M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.74
PE Ratio (ttm)	-1.18
Forward PE	n/a
Analyst	Buy

Ask	6.79
Volume	730,702
Avg. Volume (20D)	1,285,383
Open	6.68
Previous Close	6.62
Day's Range	6.42 - 6.83
52-Week Range	6.07 - 19.71
Beta	undefined

About PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal re...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 25, 2019

Employees 452

Stock Exchange NASDAQ

Ticker Symbol PHAT

Website https://www.phathompharma.com

Analyst Forecast

According to 4 analyst ratings, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 283.76% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Phathom Pharmaceuticals Inc. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of $26.04M, reflecting a 3.72K% YoY growth and earnings per share of -1.07, making a -23.02% decrease YoY.

Why Price Moved

10 months ago · Source

-6.58%

Phathom Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

News

1 month ago · zacks.com

Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround

Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn...

1 month ago · zacks.com

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know

Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & C...

2 months ago · zacks.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago.